Predictors of Outcomes After Surgery for Chronic Thromboembolic Pulmonary Hypertension

Yusuke Sakurai, Yoshiyuki Takami, Kentaro Amano, Yoshiro Higuchi, Kiyotoshi Akita, Mika Noda, Masato Tochii, Michiko Ishida, Hiroshi Ishikawa, Motomi Ando, Yukio Ozaki, Yasushi Takagi

Research output: Contribution to journalArticle

Abstract

Background: Pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) is technically demanding. We tried to identify the predictors for short- and long-term outcomes after PEA for CTEPH with aggressive use of pulmonary vasodilators, including epoprostenol sodium. Methods: From 2005 to 2013, 122 CTEPH patients, whose preoperative mean pulmonary artery pressure (mPAP) was 47 ± 10 mm Hg and pulmonary vascular resistance was 847 ± 373 dynes/s/cm5, underwent PEA with hypothermic circulatory arrest. Before PEA, all patients underwent pulmonary vasodilator therapy, including epoprostenol sodium of 2 to 6 ng/kg/min. We collected the perioperative and follow-up data retrospectively to identify the predictors for early and late outcomes after PEA. Results: In-hospital mortality was 7.4% (n = 9). Predictors for in-hospital death were age older than 65 years and New York Heart Association Functional Classification IV. Among the 113 PEA survivors, the mPAP and pulmonary vascular resistance significantly decreased. After the median follow-up of 6.8 years, the overall survival rates were 91.8%, 89.2%, 89.2%, 89.2%, and 86.1%, and the cardiac events-free rates were 100%, 98.1%, 95.8%, 85.5%, and 49.0%, at 1, 3, 5, 7, and 10 years, respectively, in the Kaplan-Meier model. A multivariate Cox proportional hazard model identified postoperative mPAP exceeding 30 mm Hg as the only predictor for late cardiac events. Conclusions: Early and late outcomes of PEA for CTEPH with perioperative aggressive pulmonary vasodilator treatment seem satisfactory. However, residual pulmonary hypertension remains challenging to achieve further improvement of late outcomes.

Original languageEnglish
Pages (from-to)1154-1161
Number of pages8
JournalAnnals of Thoracic Surgery
Volume108
Issue number4
DOIs
Publication statusPublished - 10-2019

Fingerprint

Pulmonary Hypertension
Endarterectomy
Lung
Vasodilator Agents
Pulmonary Artery
Epoprostenol
Pressure
Vascular Resistance
Hospital Mortality
Proportional Hazards Models
Survivors
Survival Rate
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Sakurai, Y., Takami, Y., Amano, K., Higuchi, Y., Akita, K., Noda, M., ... Takagi, Y. (2019). Predictors of Outcomes After Surgery for Chronic Thromboembolic Pulmonary Hypertension. Annals of Thoracic Surgery, 108(4), 1154-1161. https://doi.org/10.1016/j.athoracsur.2019.03.100
Sakurai, Yusuke ; Takami, Yoshiyuki ; Amano, Kentaro ; Higuchi, Yoshiro ; Akita, Kiyotoshi ; Noda, Mika ; Tochii, Masato ; Ishida, Michiko ; Ishikawa, Hiroshi ; Ando, Motomi ; Ozaki, Yukio ; Takagi, Yasushi. / Predictors of Outcomes After Surgery for Chronic Thromboembolic Pulmonary Hypertension. In: Annals of Thoracic Surgery. 2019 ; Vol. 108, No. 4. pp. 1154-1161.
@article{85fe65ee4dc74b15805d585ece184257,
title = "Predictors of Outcomes After Surgery for Chronic Thromboembolic Pulmonary Hypertension",
abstract = "Background: Pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) is technically demanding. We tried to identify the predictors for short- and long-term outcomes after PEA for CTEPH with aggressive use of pulmonary vasodilators, including epoprostenol sodium. Methods: From 2005 to 2013, 122 CTEPH patients, whose preoperative mean pulmonary artery pressure (mPAP) was 47 ± 10 mm Hg and pulmonary vascular resistance was 847 ± 373 dynes/s/cm5, underwent PEA with hypothermic circulatory arrest. Before PEA, all patients underwent pulmonary vasodilator therapy, including epoprostenol sodium of 2 to 6 ng/kg/min. We collected the perioperative and follow-up data retrospectively to identify the predictors for early and late outcomes after PEA. Results: In-hospital mortality was 7.4{\%} (n = 9). Predictors for in-hospital death were age older than 65 years and New York Heart Association Functional Classification IV. Among the 113 PEA survivors, the mPAP and pulmonary vascular resistance significantly decreased. After the median follow-up of 6.8 years, the overall survival rates were 91.8{\%}, 89.2{\%}, 89.2{\%}, 89.2{\%}, and 86.1{\%}, and the cardiac events-free rates were 100{\%}, 98.1{\%}, 95.8{\%}, 85.5{\%}, and 49.0{\%}, at 1, 3, 5, 7, and 10 years, respectively, in the Kaplan-Meier model. A multivariate Cox proportional hazard model identified postoperative mPAP exceeding 30 mm Hg as the only predictor for late cardiac events. Conclusions: Early and late outcomes of PEA for CTEPH with perioperative aggressive pulmonary vasodilator treatment seem satisfactory. However, residual pulmonary hypertension remains challenging to achieve further improvement of late outcomes.",
author = "Yusuke Sakurai and Yoshiyuki Takami and Kentaro Amano and Yoshiro Higuchi and Kiyotoshi Akita and Mika Noda and Masato Tochii and Michiko Ishida and Hiroshi Ishikawa and Motomi Ando and Yukio Ozaki and Yasushi Takagi",
year = "2019",
month = "10",
doi = "10.1016/j.athoracsur.2019.03.100",
language = "English",
volume = "108",
pages = "1154--1161",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "4",

}

Sakurai, Y, Takami, Y, Amano, K, Higuchi, Y, Akita, K, Noda, M, Tochii, M, Ishida, M, Ishikawa, H, Ando, M, Ozaki, Y & Takagi, Y 2019, 'Predictors of Outcomes After Surgery for Chronic Thromboembolic Pulmonary Hypertension', Annals of Thoracic Surgery, vol. 108, no. 4, pp. 1154-1161. https://doi.org/10.1016/j.athoracsur.2019.03.100

Predictors of Outcomes After Surgery for Chronic Thromboembolic Pulmonary Hypertension. / Sakurai, Yusuke; Takami, Yoshiyuki; Amano, Kentaro; Higuchi, Yoshiro; Akita, Kiyotoshi; Noda, Mika; Tochii, Masato; Ishida, Michiko; Ishikawa, Hiroshi; Ando, Motomi; Ozaki, Yukio; Takagi, Yasushi.

In: Annals of Thoracic Surgery, Vol. 108, No. 4, 10.2019, p. 1154-1161.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Predictors of Outcomes After Surgery for Chronic Thromboembolic Pulmonary Hypertension

AU - Sakurai, Yusuke

AU - Takami, Yoshiyuki

AU - Amano, Kentaro

AU - Higuchi, Yoshiro

AU - Akita, Kiyotoshi

AU - Noda, Mika

AU - Tochii, Masato

AU - Ishida, Michiko

AU - Ishikawa, Hiroshi

AU - Ando, Motomi

AU - Ozaki, Yukio

AU - Takagi, Yasushi

PY - 2019/10

Y1 - 2019/10

N2 - Background: Pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) is technically demanding. We tried to identify the predictors for short- and long-term outcomes after PEA for CTEPH with aggressive use of pulmonary vasodilators, including epoprostenol sodium. Methods: From 2005 to 2013, 122 CTEPH patients, whose preoperative mean pulmonary artery pressure (mPAP) was 47 ± 10 mm Hg and pulmonary vascular resistance was 847 ± 373 dynes/s/cm5, underwent PEA with hypothermic circulatory arrest. Before PEA, all patients underwent pulmonary vasodilator therapy, including epoprostenol sodium of 2 to 6 ng/kg/min. We collected the perioperative and follow-up data retrospectively to identify the predictors for early and late outcomes after PEA. Results: In-hospital mortality was 7.4% (n = 9). Predictors for in-hospital death were age older than 65 years and New York Heart Association Functional Classification IV. Among the 113 PEA survivors, the mPAP and pulmonary vascular resistance significantly decreased. After the median follow-up of 6.8 years, the overall survival rates were 91.8%, 89.2%, 89.2%, 89.2%, and 86.1%, and the cardiac events-free rates were 100%, 98.1%, 95.8%, 85.5%, and 49.0%, at 1, 3, 5, 7, and 10 years, respectively, in the Kaplan-Meier model. A multivariate Cox proportional hazard model identified postoperative mPAP exceeding 30 mm Hg as the only predictor for late cardiac events. Conclusions: Early and late outcomes of PEA for CTEPH with perioperative aggressive pulmonary vasodilator treatment seem satisfactory. However, residual pulmonary hypertension remains challenging to achieve further improvement of late outcomes.

AB - Background: Pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) is technically demanding. We tried to identify the predictors for short- and long-term outcomes after PEA for CTEPH with aggressive use of pulmonary vasodilators, including epoprostenol sodium. Methods: From 2005 to 2013, 122 CTEPH patients, whose preoperative mean pulmonary artery pressure (mPAP) was 47 ± 10 mm Hg and pulmonary vascular resistance was 847 ± 373 dynes/s/cm5, underwent PEA with hypothermic circulatory arrest. Before PEA, all patients underwent pulmonary vasodilator therapy, including epoprostenol sodium of 2 to 6 ng/kg/min. We collected the perioperative and follow-up data retrospectively to identify the predictors for early and late outcomes after PEA. Results: In-hospital mortality was 7.4% (n = 9). Predictors for in-hospital death were age older than 65 years and New York Heart Association Functional Classification IV. Among the 113 PEA survivors, the mPAP and pulmonary vascular resistance significantly decreased. After the median follow-up of 6.8 years, the overall survival rates were 91.8%, 89.2%, 89.2%, 89.2%, and 86.1%, and the cardiac events-free rates were 100%, 98.1%, 95.8%, 85.5%, and 49.0%, at 1, 3, 5, 7, and 10 years, respectively, in the Kaplan-Meier model. A multivariate Cox proportional hazard model identified postoperative mPAP exceeding 30 mm Hg as the only predictor for late cardiac events. Conclusions: Early and late outcomes of PEA for CTEPH with perioperative aggressive pulmonary vasodilator treatment seem satisfactory. However, residual pulmonary hypertension remains challenging to achieve further improvement of late outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85071402967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071402967&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2019.03.100

DO - 10.1016/j.athoracsur.2019.03.100

M3 - Article

C2 - 31075248

AN - SCOPUS:85071402967

VL - 108

SP - 1154

EP - 1161

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 4

ER -